Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

IPO Update: Intellia Launch Shows CRISPR Still Excites While Others Struggle

Executive Summary

Intellia Therapeutics Inc. sold more shares in its initial public offering than originally expected and the CRISPR/Cas9 specialist did so at the top of its proposed price range, proving that investors remain excited about gene editing, but have less enthusiasm for other early-stage therapeutics firms.


Related Content

Biopharma IPOs In 2016: Fewer Offerings, Better Returns As Firms Adjust To Market Realities
IPO Update: Values Slip As Four More Biopharma Firms Go Public In October
Year's First 4 IPOs Go South As Proteostasis, AveXis Launch
FINANCE ROUNDUP: VC Investment Not Hurt Yet By Biotech Stock Slump
IPO UPDATE: Bubble worries heighten after another big Alzheimer's offering
Oncobiologics raises $31m for biosimilars; RaNA, Ra, SutroVax add VC cash
Lilly and Novartis put VC cash into Aeglea's series B
TABLE: In turbulent week, 2 IPOs price, 6 test waters
Zeria/Tillotts in $100m-plus deal for CPP's FAP drug
Novartis Option Fund licenses option on Viamet's metalloenzyme programme


Related Companies